Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-24 @ 11:50 PM
NCT ID:
NCT00945451
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed non-small cell lung cancer
* Locally advanced disease
* No metastatic disease
* Unable to undergo surgery after concurrent chemoradiotherapy
* Must have 1-3 tumor target masses \< 5 cm in greatest diameter and separated by ≥ 2 cm after concurrent chemoradiotherapy
PATIENT CHARACTERISTICS:
* WHO performance status 0-2
* Platelet count \> 100,000/mm³
* Hemoglobin \> 9 g/dL
* Neutrophil \> 1.0 x 10\^9/L
* FEV\_1 \> 30% of vital capacity
* Vital capacity \> 25% of predicted value
* DLCO \> 25% of predicted value
* LVEF ≥ 35%
* PT \> 80
* aPTT \> 35 sec
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 6 months after completion of study treatment
* Not under guardianship
* No dyspnea related to NYHA class III-IV heart failure
* No indirect signs of pulmonary arterial hypertension (pulmonary arterial systolic BP \> 45 mm Hg)
* No pulmonary acceleration time \< 100 ms
* No contraindication to fiducial insertion
* No geographical, social, or psychological conditions that would interfere with medical follow-up
PRIOR CONCURRENT THERAPY:
* Docetaxel and platinum-based drugs with concurrent irradiation allowed
* No prior surgery or surgery after the first phase of treatment with concurrent chemoradiotherapy
* No prior irradiation to lung
* No concurrent participation in another study trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT00945451
Study Brief:
Protocol Section:
NCT00945451